Business Wire

Curia to Acquire US-Based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Share

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts, and Texas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005230/en/

Established in 2009 in the Bay Area, LakePharma applies its range of technology platforms to advance projects from discovery to development to manufacturing, namely cell-line development, bioexpression systems and viral vector production systems. Almost a quarter of its employees hold Ph.D.s, bringing expertise in all major biologics segments: mammalian, microbial, plasmid DNA, mRNA, monoclonal antibodies, and viral vector, including cell and gene therapy. LakePharma has contributed to the development of more than 200 therapeutic or diagnostic products and served more than 1,500 customers, including 22 of the top 25 global biopharmaceutical companies.

After the transaction close, the combined company will provide deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production. LakePharma’s six facilities and 235 employees will join with Curia’s 21 sites and more than 3,100 employees to offer clients an end-to-end partnership in drug discovery, formulation and process development as well as drug substance and drug product clinical and commercial manufacturing. Curia recently announced it has also signed a definitive agreement to acquire Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California.

“LakePharma will expand our integrated approach to provide biotech and pharmaceutical companies with small and large molecule research, development and manufacturing solutions,” said Curia Chairman & CEO John Ratliff. “Funding and innovation in the biotech sector remains strong. Our combined capabilities will enable us to partner with our customers by seamlessly providing LakePharma’s multi-modality innovation and speed along with fill-finish solutions from Curia. Our agreements with LakePharma and Integrity Bio demonstrate our commitment to expanding and deepening our biologics capabilities to help our customers advance from curiosity to cure.”

Hua Tu, Ph.D., founder and CEO of LakePharma, said: “LakePharma is delighted to join the Curia family. Over the last 12 years, we have built a strong brand as 'The Biologics Company,' a talented and dedicated employee team, and a loyal and supportive client base. We are excited to join Curia’s global network, including commercial manufacturing capabilities, in delivering end-to-end integrated biologics solutions to our pharma and biotech clients.”

RBC Capital Markets, LLC is serving as exclusive financial adviser to Curia and Nelson Mullins Riley & Scarborough LLP is serving as Curia’s legal counsel. Goldman Sachs & Co. LLC is serving as financial adviser to LakePharma, and Fenwick & West LLP is serving as LakePharma’s legal counsel. The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.

About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

About LakePharma
LakePharma is a U.S.-based biologics CRDMO with operations in California, Texas, and Massachusetts. This biotech company specializes in the production and evaluation of DNA vectors, viral vectors, cell lines, proteins, antibodies, mRNA and conjugates while providing integrated solutions bridging discovery, engineering, development, and GMP manufacturing. LakePharma has contributed to the development of 200+ therapeutic or diagnostic products and strives to develop hundreds more. Learn more at www.LakePharma.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate:
Sue Zaranek
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Media Communications:
Debra Harrsch
Brandwidth Solutions LLC
+1 215 997 8575
dharrsch@bwsmarketing.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Workiva Extends Value of Cloud Platform with Launch of New SaaS Marketplace28.7.2021 10:15:00 CEST | Press release

Workiva Inc. (NYSE:WK), today launched The Workiva Marketplace, filled with more than 140 Workiva-built and partner templates, services and 60 no-code connectors that streamline existing processes and solve new business problems all within the Workiva cloud platform’s connected and secure ecosystem. The Workiva Marketplace’s offerings include: process checklists, carefully organized and linked reports, style guides, perfectly formatted presentations, and more. Accounting, audit, financial planning & analysis, financial services, and legal teams can easily add templates or connectors directly into an existing Workiva workspace and optimize workflow with process automation, practical examples, and industry best practices. Comments on the News: “There is an enormous opportunity for organizations to scale their business operations efficiently and cost effectively by leveraging Workiva’s connected ecosystem,” said Julie Iskow, COO of Workiva. “The Workiva Marketplace allows users to find to

Nordic Enterprises Moving Forward with SAP S/4HANA Initiatives to Meet Challenges of COVID-1928.7.2021 10:00:00 CEST | Press release

Enterprises in the Nordics are addressing the challenges of the COVID-19 pandemic by adopting cloud services and reworking their IT strategies and technology roadmaps, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2021 ISG Provider Lens™ SAP HANA Ecosystem Services report for the Nordics finds large-scale, long-term system transformations in the region, including SAP S/4HANA projects, have continued despite slowing down briefly early in the pandemic. To continue operating under the new business conditions, many companies are moving their workloads to the cloud. “With help from service providers, companies in the Nordics continue to innovate with SAP applications,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “Providers’ skilled management of offshore services have kept SAP projects on plan, with only minor delays due to the pandemic.” Many enterprises

Värde Partners Agrees €96 Million Sale of Hotel Barcelona Apolo to Meliá28.7.2021 10:00:00 CEST | Press release

Värde Partners, a leading global alternative investment firm, announced it has agreed to the sale of Hotel Barcelona Apolo to Meliá Hotels International, the current hotel operator, for €96 million. The transaction followed an open bidding process that attracted interest from more than 20 institutional investors. The sale was agreed through Dospuntos Asset Management, a Värde-controlled real estate company in Spain, formed in December 2017 from the residential developer Vía Célere. Since the acquisition of the hotel in 2015 Värde has executed a series of value creation initiatives, including refinancing the business and delivering a comprehensive investment program, to establish Hotel Barcelona Apolo as a leading destination for international tourists and corporate events. “The timing of the sale reflects our conviction in the underlying quality of the hotel, and the enduring appeal of Barcelona as a destination for international capital. There was strong demand for the asset demonstra

Aqara Expands to Amazon UK28.7.2021 10:00:00 CEST | Press release

Aqara, a provider for smart home products, announced the launch of its first Amazon store in Europe, the Aqara Amazon UK store. Starting from July 28, 2021, a comprehensive suite of Aqara products will be made available on Amazon UK to residents not only in the UK, but also in dozens of European countries that are covered in the Amazon network. Aqara has been selling smart home products in Europe since 2020 via dozens of authorized distributors, and has become one of the most popular brands among the European smart home community for the high product quality, the accessible prices and the seamless integration with major ecosystems including Apple HomeKit, Amazon Alexa, Google Assistant, and more. The launch of Aqara’s first Amazon Europe store marks another milestone for the fast-growing brand, offering millions of European consumers an easy and convenient access to the Aqara product lineup. Following its UK Amazon store, Aqara is expected to add two more brand stores on Amazon France

DIC, Debut Biotech Team Up to Develop and Bio-Manufacture Natural Pigments for More Sustainable Food Colorants and Cosmetics28.7.2021 09:55:00 CEST | Press release

DIC Corporation (TOKYO:4631) announced a joint research development agreement with California-based biotech startup Debut Biotechnology, Inc., further enhancing DIC efforts to develop natural pigments for food colorants and cosmetics. In recent years, increasingly urgent climate concerns have increased global consumer demand for biodegradable, naturally derived colorants—notably in foods and cosmetics—to replace synthetic petroleum-derived colorants. This rapidly increasing consumer demand has motivated major global brands to seek out more sustainable materials for their products. Unfortunately, the increasing efforts to extract useful pigments from natural materials, including flowers or plants, continue to face significant commercialization challenges, including unacceptably low yields, excessive post-extraction waste generation, and environmental burdens, such as land and water use. Moreover, problems specific to agriculture, such as increasingly unstable weather as well as qualitat

Ipsen Strengthens Its Pre-clinical Oncology Pipeline With an Exclusive Worldwide-collaboration With BAKX Therapeutics Inc. for BKX-001, Targeting the Apoptosis Pathway27.7.2021 19:01:00 CEST | Press release

Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and BAKX Therapeutics Inc. have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture and commercialize BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors. Apoptosis is the naturally occurring process of programmed cell death. Deregulated apoptosis can lead to uncontrolled cell division and the development of a tumor.2 The apoptosis cell-signaling pathway has been proven to be a target for cancer therapy with the development and approval of BCL-2 inhibitors for the treatment of certain hematological malignancies.3 BAX is a novel target in this pathway that is downstream of all anti-apoptotic proteins like BCL-2, BCL-XL, MCL-1 etc.4 Direct activation of BAX has several possible outcomes as an investigational cancer therapy, potentially addressing multiple tumor types and the resistance encountered while target

Daikin Industries Becomes OCSiAl Shareholder27.7.2021 18:55:00 CEST | Press release

Japanese giant Daikin Industries, Ltd, has become a shareholder of the world’s largest producer of graphene nanotubes, OCSiAl, following three years of collaboration in developing graphene nanotube applications as a next-generation additive. Together, the companies are determined to develop high-performance materials and establish new markets. The signing of a share subscription agreement between Daikin Industries, a world-leading air conditioning company and a pioneer in fluorine technologies, and OCSiAl, the world’s largest producer of graphene nanotubes and related industrial solutions, was supported by prior joint developments and market evaluation. In accordance with the terms of the agreement, the valuation of OCSiAl is about USD $2 billion. Along with the subscription agreement, the two companies have signed a cooperation agreement to develop, produce, and market graphene nanotube solutions for next-generation Li-ion batteries and fluoropolymers, which comprise a substantial par

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom